XA5-94430-87605
2 vaccinations
1 coded response
4 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 980 / WA
- Registered
- 2021-02-12
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-26
Dose 1 — Pfizer-BioNTech
-
2021-02-12
Registered in v-safe
-
2021-02-12
Dose 2 — Pfizer-BioNTech
- 2021-02-12
- 2021-02-12
- 2021-08-15
-
2022-02-12
Survey response — 12 months, dose 2MedDRA: Oropharyngeal pain, Rhinorrhoea — Feeling: Good · Be unable to work or attend schoolFree text: Runny nose and sore throatMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-26 | Pfizer-BioNTech | |
| 2 | 2021-02-12 | Pfizer-BioNTech |
Free text
Release 11 — 12 months, dose 2
Symptoms: Runny nose and sore throat
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release